Marker Therapeutics Inc Sustainability Reports
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The company focuses on the development of multi-antigen targeted T cell therapies designed to activate a patient's own immune system.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300ZJ2JUDG0FI5Y49
FIGI: BBG001SKLLN7
3 reports from 2017 to 2024
